- Home
- MBIO vs JAGX Comparison
MBIO vs JAGX Comparison
Compare MBIO & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBIO
- JAGX
- Stock Information
- Founded
- MBIO 2015
- JAGX 2013
- Country
- MBIO United States
- JAGX United States
- Employees
- MBIO N/A
- JAGX N/A
- Industry
- MBIO Biotechnology: Pharmaceutical Preparations
- JAGX Biotechnology: Pharmaceutical Preparations
- Sector
- MBIO Health Care
- JAGX Health Care
- Exchange
- MBIO Nasdaq
- JAGX Nasdaq
- Market Cap
- MBIO 7.3M
- JAGX 7.4M
- IPO Year
- MBIO N/A
- JAGX N/A
- Fundamental
- Price
- MBIO $1.12
- JAGX $5.88
- Analyst Decision
- MBIO Strong Buy
- JAGX
- Analyst Count
- MBIO 1
- JAGX 0
- Target Price
- MBIO $100.00
- JAGX N/A
- AVG Volume (30 Days)
- MBIO 1.1M
- JAGX 247.5K
- Earning Date
- MBIO 05-27-2025
- JAGX 05-15-2025
- Dividend Yield
- MBIO N/A
- JAGX N/A
- EPS Growth
- MBIO N/A
- JAGX N/A
- EPS
- MBIO N/A
- JAGX N/A
- Revenue
- MBIO N/A
- JAGX $11,689,000.00
- Revenue This Year
- MBIO N/A
- JAGX $22.41
- Revenue Next Year
- MBIO N/A
- JAGX $30.00
- P/E Ratio
- MBIO N/A
- JAGX N/A
- Revenue Growth
- MBIO N/A
- JAGX 19.75
- 52 Week Low
- MBIO $1.01
- JAGX $4.02
- 52 Week High
- MBIO $65.00
- JAGX $502.50
- Technical
- Relative Strength Index (RSI)
- MBIO 36.90
- JAGX 37.09
- Support Level
- MBIO $1.01
- JAGX $5.30
- Resistance Level
- MBIO $1.22
- JAGX $13.20
- Average True Range (ATR)
- MBIO 0.07
- JAGX 1.49
- MACD
- MBIO 0.02
- JAGX -0.57
- Stochastic Oscillator
- MBIO 52.38
- JAGX 7.30
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
About JAGX Jaguar Health Inc.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.